These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 20926828)

  • 1. Use of tissue cross-reactivity studies in the development of antibody-based biopharmaceuticals: history, experience, methodology, and future directions.
    Leach MW; Halpern WG; Johnson CW; Rojko JL; MacLachlan TK; Chan CM; Galbreath EJ; Ndifor AM; Blanset DL; Polack E; Cavagnaro JA
    Toxicol Pathol; 2010 Dec; 38(7):1138-66. PubMed ID: 20926828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogate approaches in development of monoclonal antibodies.
    Bornstein GG; Klakamp SL; Andrews L; Boyle WJ; Tabrizi M
    Drug Discov Today; 2009 Dec; 14(23-24):1159-65. PubMed ID: 19853060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survey results on the use of the tissue cross-reactivity immunohistochemistry assay.
    Bussiere JL; Leach MW; Price KD; Mounho BJ; Lightfoot-Dunn R
    Regul Toxicol Pharmacol; 2011 Apr; 59(3):493-502. PubMed ID: 20951178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational strategies for development of monoclonal antibodies from discovery to the clinic.
    Tabrizi MA; Bornstein GG; Klakamp SL; Drake A; Knight R; Roskos L
    Drug Discov Today; 2009 Mar; 14(5-6):298-305. PubMed ID: 19152840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical safety of monoclonal antibodies.
    Tabrizi MA; Roskos LK
    Drug Discov Today; 2007 Jul; 12(13-14):540-7. PubMed ID: 17631248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of characterization of FITC-labeled antibodies used in tissue cross-reactivity studies.
    Takai H; Kato A; Nakamura T; Tachibana T; Sakurai T; Nanami M; Suzuki M
    Acta Histochem; 2011 Jul; 113(4):472-6. PubMed ID: 20546862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classic and evolving approaches to evaluating cross reactivity of mAb and mAb-like molecules - A survey of industry 2008-2019.
    MacLachlan TK; Price S; Cavagnaro J; Andrews L; Blanset D; Cosenza ME; Dempster M; Galbreath E; Giusti AM; Heinz-Taheny KM; Fleurance R; Sutter E; Leach MW
    Regul Toxicol Pharmacol; 2021 Apr; 121():104872. PubMed ID: 33485926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow cytometry in preclinical drug development.
    Lappin PB
    Methods Mol Biol; 2010; 598():303-21. PubMed ID: 19967522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development.
    Mikulskis A; Yeung D; Subramanyam M; Amaravadi L
    J Immunol Methods; 2011 Feb; 365(1-2):38-49. PubMed ID: 21130095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical safety evaluation of monoclonal antibodies.
    Lynch CM; Grewal IS
    Handb Exp Pharmacol; 2008; (181):19-44. PubMed ID: 18071940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
    Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions.
    Finlay WJ; Cunningham O; Lambert MA; Darmanin-Sheehan A; Liu X; Fennell BJ; Mahon CM; Cummins E; Wade JM; O'Sullivan CM; Tan XY; Piche N; Pittman DD; Paulsen J; Tchistiakova L; Kodangattil S; Gill D; Hufton SE
    J Mol Biol; 2009 May; 388(3):541-58. PubMed ID: 19285987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections.
    Wang X; Campoli M; Cho HS; Ogino T; Bandoh N; Shen J; Hur SY; Kageshita T; Ferrone S
    J Immunol Methods; 2005 Apr; 299(1-2):139-51. PubMed ID: 15896802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative strategies for toxicity testing of species-specific biopharmaceuticals.
    Bussiere JL; Martin P; Horner M; Couch J; Flaherty M; Andrews L; Beyer J; Horvath C
    Int J Toxicol; 2009; 28(3):230-53. PubMed ID: 19546261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical efficacy and safety models for mAbs: the challenge of developing effective model systems.
    Dixit R; Coats S
    IDrugs; 2009 Feb; 12(2):103-8. PubMed ID: 19204884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLAMatchmaker-based analysis of human monoclonal antibody reactivity demonstrates the importance of an additional contact site for specific recognition of triplet-defined epitopes.
    Duquesnoy RJ; Mulder A; Askar M; Fernandez-Vina M; Claas FH
    Hum Immunol; 2005 Jul; 66(7):749-61. PubMed ID: 16112022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specificity and binding properties of a single-chain T cell receptor.
    Schlueter CJ; Schodin BA; Tetin SY; Kranz DM
    J Mol Biol; 1996 Mar; 256(5):859-69. PubMed ID: 8601837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a monoclonal antibody specific for activated endothelial cells to quantitate angiogenesis in vivo in zebrafish after drug treatment.
    Seng WL; Eng K; Lee J; McGrath P
    Angiogenesis; 2004; 7(3):243-53. PubMed ID: 15609079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for reactive intermediates and toxicity assessment in drug discovery.
    Caldwell GW; Yan Z
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):47-60. PubMed ID: 16445117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory forum opinion piece*: tissue cross-reactivity studies: what constitutes an adequate positive control and how do we report positive staining?
    Geoly FJ
    Toxicol Pathol; 2014 Aug; 42(6):954-6. PubMed ID: 23847038
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.